Drug eluting balloons for the treatment of coronary artery disease: What can we expect?

Figure 1 Subtotal long-segment in-stent re-restenosis of the right coronary artery treated with drug eluting balloons. A: Pre-percutaneous coronary intervention; B: After recanalization; C: Angiographic 6-mo follow-up.

Figure 2 Proximal de novo stenosis of the native left circumflex coronary artery treated with “plain old balloon angioplasty” using a drug eluting balloon. A: Pre-percutaneous coronary intervention (PCI); B: Immediately after PCI; C: Angiographic 6-mo follow-up.

Figure 3 Treatment of in-stent-restenosis using a drug eluting balloon (paclitaxel-releasing balloon) vs a drug-eluting stent (paclitaxel-eluting stent). Left columns: Rate of binary in-segment restenosis (%) after 6 mo; Right columns: Major adverse cardiac events (MACE, including target lesion revascularization, myocardial infarction, stent thrombosis, or death) (%) after 12 mo[9]. DEB: Drug-eluting balloon; DES: Drug-eluting stents.

Figure 4 Treatment of small vessels (diameter < 2. 8 mm) using a drug eluting balloon (paclitaxel-eluting balloon). Left columns: Rate of binary in-segment restenosis (%) after 6 mo; Right columns: Major adverse cardiac events (MACE) (%) after 12 mo[10]. DEB: Drug-eluting balloon.